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A B S T R A C T
Four Co(III) ternary complexes with the composition of [(Co(4 N))2(quin)](ClO4)4 or [(Co(4 N))2(quinS)](ClO4)3, where 4 N = tris(2-aminoethyl)amine (tren) or tris
(2-pyridylmethyl)amine (tpa), quinH2 = quinizarin (1,4-dihydroxy-9,10-anthraquinone), quinSH3 = quinizarin-2-sulfonic acid (1,4-dihydroxy-9,10-anthraquinone-
2-sulfonic acid), were synthesized, characterized and their human serum albumin (HSA) binding capabilities were also tested. The complexes can be considered as
likely chaperons of quinizarins which are structural models for anthracycline-based anticancer drugs like doxorubicin. All the Co(III) complexes are dinuclear and
were isolated as mixture of isomers. Comparison of the cyclic voltammograms of the free ligands and the appropriate Co(III) complexes revealed that the new signals
belonging to reversible processes in the range −400–0 mV (vs. Ag/AgCl) for the complexes can be attributed to the reversible reduction of the Co(III) centre. These
potentials are in the range of typical (O,O) chelated Co(III) ternary complexes bearing 4 N donor ligands and follow the order being more positive for the tpa
containing complexes. Presence of the sulfonate group in the quinizarin results in slightly more negative reduction potential of the Co(III) complexes. HSA binding
capabilities of the quinH2 and quinSH3 ligands as well as the appropriate complexes showed that quinSH3 has higher affinity to the protein than quinH2 while none of
the complexes seem to bind to HSA.
1. Introduction
Drawbacks associated with the lack of selectivity of square planar Pt
(II) complexes currently used in the treatment of some tumors may be
eliminated by taking into consideration the differences of healthy and
tumor cells. For this purpose, inert Co(III) complexes for instance may
serve as promising candidates since with suitable donor atom en-
vironment these compounds can undergo selective reduction in the
more reductive environment of the cancer cells caused by hypoxia. As a
consequence, ligands with anticancer potential can be released upon
dissociation of the less stable Co(II) complex within the cancer cell.
Anthracyclines are a class of antineoplastic drugs derived from
Streptomyces sp. First anthracyclines were isolated from Streptomyces
peucetius and were named doxorubicin and daunorubicin. These qui-
nizarin (1,4-dihydroxy-9,10-anthraquinone, quinH2) based molecules
with anticancer activity play an important role in the treatment of
breast, ovarian, lung cancer, a range of neuroblastomas and leukemia
[1–4]. The cellular target of doxorubicin is topoisomerase II enzyme. By
interfering with the topoisomerase II-DNA complex doxorubicin in-
hibits the enzyme thus triggers cell death because of the formation of
double-strand breaks of DNA by the direct intercalation with DNA du-
plex. This event inhibits the DNA replication and transcription to mRNA
[1,5–8]. Doxorubicin and other anthracycline drugs suffer from dose-
dependent acute and chronic toxicity the latter being due to
cardiotoxicity. The cardiotoxicity of doxorubicin is connected to iron-
mediated various electron transfer processes resulting in the formation
of reactive oxygen species (ROS) and subsequent generation of oxida-
tive phosphorylation and lipoperoxidation [9–18]. Recently it was also
reported that doxorubicin-induced cardiotoxicity is mediated by to-
poisomerase-IIβ in heart muscle cells [8]. Anthracyclines with O-donors
in chelate forming position are good metal ion complexing agents. A
large number of literature data indicate that endogenous iron plays an
important role in the dose-dependent cardiotoxicity of the anthracy-
cline drugs. Iron is believed to be involved in ROS formation and the
redox cycling of quinone form of doxorubicin would enable to increase
the cellular levels of iron by mobilizing of iron from ferritin resulting in
higher level of oxidative stress. On contrary to the “ROS hypothesis” it
was also demonstrated that on the one hand iron chelators like dexra-
zoxane are capable of decreasing the doxorubicin-related cardiotoxi-
city, on the other hand none of the tested antioxidants proved to be
protective against chronic cardiotoxicity in clinical settings [4,19–21].
Beside iron the complexation of anthracyclines with some other
metal ions were also studied. In earlier works Garnier-Suillerot et al.
have studied the complex formation between Fe(III) or Pd(II) and
doxorubicin, daunorubicin or carminomycin. It was found that all these
anthracyclines form stable tris complexes with the Fe(III) while with Pd
(II) bis and dimeric (Pd:ligand = 2:2) complexes were assumed. Despite
the high stability of the Fe(III) complexes, complex dissociation
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followed by intercalation of the unbound ligand into the DNA base pairs
was observed in in vitro studies. Furthermore, all these complexes
displayed anticancer activity against P-388 leukemia cells [22–24]. The
complexation of doxorubicin with Cu(II) and Fe(II) was also in-
vestigated and found that [CuL2] or [FeL3] are the major species at
pH = 7.0 [25]. In a more recent study the interaction of doxorubicin
and its structural model, 1,4-dihydroxy-9,10-anthraquinone-2-sulfonate
(quinizarine-2-sulfonic acid, quinSH3), with Ni(II) was studied. The bis-
ligand complexes, found to be present in solution, are able to bind to
calf thymus DNA. Notably, the drug complex was reported to have
much higher stability than the other model complex [26].
Regarding the simpler structural model of the anthracyclines, qui-
nizarin, its dinuclear Ru(III) and Os(II) complexes in which the quini-
zarin acts as a bridging ligand were synthesized and characterized. In
both cases the redox study of the complexes revealed the non-innocent
behaviour of the anthraquinone and several oxidation and reduction
steps of the complexes were detected [27,28].
The aim of this work was to synthesize and characterize novel mixed
ligand Co(III) complexes bearing the quinH2 ligand or its sulfonate
derivative quinSH3 as models for the costlier anthracycline drugs, in
order to explore the nuclearity, stability, kinetic and redox behaviour of
the complexes. In these species four coordination sites of the central Co
(III) is taken by tripodal tetramines in order to provide appropriate
redox features [29,30]. Tris(2-aminoethyl)amine (tren) and tris(2-pyr-
idylmethyl)amine (tpa) tripodal amines were selected for the studies.
According to our hypothesis these Co(III) mixed ligand species may
undergo selective dissociation under hypoxic conditions releasing the
bioligand mostly in tumor cells. In an ideal case if the ligand is released
selectively in the tumor cells it can be assumed that the dose of the
anthracycline drug administered in metal complexed form can be
lowered, and the dose-dependent cardiotoxicity of the anthracyclines
can be minimized. Herein we present the synthesis, characterization
and human serum albumin (HSA) binding results of four novel Co(III)
ternary complexes with the model quinH2 or quinSH3 ligands accessed
by elemental analysis, NMR and infrared (IR) spectroscopy, electro-
spray ionization mass spectrometry (ESI-MS), cyclic voltammetry (CV),
UV–visible (UV–Vis) and fluorimetric methods. The formulae of the
used ligands and the complexes are summarized in Fig. 1.
2. Experimental
2.1. Materials and reagents
CoCl2∙6H2O, NaNO2, tren, NaClO4, NH4PF6, 1,4-dihydroxy-9,10-
anthraquinone (quinH2), 1,4-dihydroxy-9,10-anthraquinone-2-sulfonic
acid (quinSH3), D2O, d6-DMSO were commercial products from Merck,
Sigma-Aldrich, Reanal, Pflatz and Bauer. Tpa [31], [Co(tren)(NO2)2]Cl,
[Co(tren)Cl2]Cl, [Co(tpa)(NO2)2]Cl, [Co(tpa)Cl2]Cl [32] were synthe-
sized and purified according to literature procedures. HSA (with fatty
acids as lyophilized powder), warfarin (WF), dansylglycine (DG), n-
octanol and all buffer components (KCl, NaCl, Na2HPO4∙2H2O, KH2PO4)
were Sigma-Aldrich products in puriss quality. Milli-Q ultrapure water
was used as solvent for the samples and stock solutions. CAUTION:
Although we never have experienced any problems, perchlorate salts
are potentially explosive.
2.2. Synthesis of the complexes
2.2.1. [(Co(tren))2(quin)](ClO4)4 (1)
QuinH2 (38 mg, 0.16 mmol) was dissolved in 10 mL isopropanol
containing 2 eq. 1M KOH (320 μL), giving a purple solution. [Co
(tren)Cl2]Cl (100 mg, 0.32 mmol), dissolved in 5 mL water, was added.
The brown/deep orange mixture was heated at reflux for 4 h. The
mixture was kept at room temperature overnight. The solid was filtered
off and NaClO4 was added to the solution in excess. Purple crystalline
solid appeared after a few hours, on standing at 4 °C. The crude product
was washed with 2 mL MeOH and recrystallized from acetonitrile. The
solid was filtered off and dried in vacuo. Yield: 72 mg (43%). 1H NMR
(400 MHz, D2O): δ/ppm = 8.46 (m, 2H, AreH); 7.94 (m, 2H, AreH);
7.46 (t, 1H, AreH); 7.37 (t, 1H, AreH); 3.94 (m, 2H, -CH2); 3.84 (m,
2H, -CH2); 3.54 (m, 4H, -CH2); 3.37 (m, 4H, -CH2); 3.24 (m, 4H, –CH2);
3.07 (m, 6H, –CH2); 2.88 (m, 2H, –CH2). (400 MHz, d6-DMSO): δ/
ppm = 8.44 (m, 2H, AreH); 7.96 (m, 2H, AreH); 7.47 (t, 1H, AreH);
7.28 (t, 1H, AreH); 5.48 (m, 4H, -NH2); 5.32 (m, 4H, -NH2); 5.24 (m,
3H, -NH2); 5.13 (m, 1H, -NH2); 3.58 (m, 4H, -CH2); 3.41 (m, 4H, -CH2);
3.21 (m, 4H, -CH2); 3.00 (m, 4H, -CH2); 2.85 (m, 4H, -CH2); 2.78 (m,
4H, -CH2). IR (KBr)/cm−1: 3260, 1543, 1422, 1105, 625. Anal.
Required for C26H42Cl4Co2N8O20∙0.8NaClO4∙0.6 H2O: C, 27.03, H, 3.77,
Fig. 1. Structure and abbreviation of the studied ligands and complexes.
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N, 9.70%. Found: C, 27.00, H, 3.78, N, 9.58%. MS (ESI, positive ion):
m/z: 444.122 ([Co(II)(tren)(quin) + H]+); 304.037 ([Co(II)(tren)
(ClO4)]+).
2.2.2. [(Co(tpa))2(quin)](ClO4)4 (2)
The synthesis was similar to that of 1, using [Co(tpa)Cl2]Cl (100 mg,
0.22 mmol), quinH2 (26 mg, 0.11 mmol), 1 M KOH (220 μL). The crude
product was washed with 2 mL MeOH and Et2O and it was re-
crystallized from water. The complex was isolated as an indigo coloured
crystalline solid. Yield: 94 mg (47%). 1H NMR (400 MHz, d6-DMSO): δ/
ppm = 9.44 (d, 0.5H, AreH); 9.37 (m, 1.5H, AreH); 9.11 (d, 0.5H,
AreH); 8.59 (d, 0.5H, AreH); 8.46 (m, 0.5H, AreH); 8.32 (m, 1.5H,
AreH); 8.24 (m, 3H, AreH); 8.12 (m, 8H, AreH); 7.85 (m, 8H, ArH);
7.57 (m, 1H, ArH); 7.41 (m, 5H, ArH); 5.86 (m, 2.5H, -CH2); 5.70 (m,
1.5H, -CH2); 5.35–5.17 (m, 6H, -CH2); 5.06–4.96 (m, 2H, -CH2). IR
(KBr)/cm−1: 3434, 3083, 1611, 1540, 1424, 1278, 1091, 770, 623.
Anal. Required for C50H42Cl4Co2N8O20∙2 H2O: C, 43.81, H, 3.38, N,
8.18%. Found: C, 43.95, H, 3.34, N, 8.26%. MS (ESI, positive ion): m/z:
588.119 ([Co(II)(tpa)(quin) + H]+); 468.099 ([(Co(II)
(tpa))2(quin)]2+); 448.034 ([Co(II)(tpa)(ClO4)]+); 174.542 ([Co(II)
(tpa)]2+).
2.2.3. [(Co(tren))2(quinS)](PF6)3 (3)
QuinSH3 (51 mg, 0.16 mmol) was dissolved in 10 mL MeOH and
2 eq. 1M KOH (320 μL), was added giving a purple solution. [Co
(tren)Cl2]Cl (100 mg, 0.32 mmol), was added and the mixture was
stirred at 60 °C for overnight. The mixture was filtered after standing at
4 °C for half a day. Purple solid appeared immidiately by adding
NH4PF6 (78 mg, 0.48 mmol). The mixture was heated at reflux to get a
clear solution and left to cool down to room temperature slowly. Purple
crystalline solid appeared. The solid was filtered off and dried in vacuo.
Yield: 78 mg (48%). 1H NMR (400 MHz, d6-DMSO): δ/ppm = 8.41 (m,
2H, AreH quinS); 7.93 (m, 2H, AreH quinS); 7.75 (s, 0.5H, AreH
quinS); 7.60 (s, 0.5H, AreH quinS); 6.02 (m, 1H, -NH2); 5.90–5.67 (m,
7H, -NH2); 5.45 (m, 2H, -NH2); 5.25 (m, 1H, -NH2); 5.06 (m, 1H, -NH2);
4.26 (m, 2H, -CH2); 3.57 (m, 2H, -CH2); 3.42 (m, 2H, -CH2); 3.25–3.11
(m, 4H, -CH2); 2.98 (m, 5H, -CH2); 2.85 (m, 7H, -CH2); 2.63 (m, 2H,
-CH2). IR (KBr)/cm−1: 1602, 1413, 1048, 639, 501, 419. Anal.
Required for C26H41Co2F18N8O7P3S: C, 26.86, H, 3.55, N, 9.64, S,
2.76%. Found: C, 26.51, H, 3.46, N, 9.95, S, 2.58%. MS (ESI, positive
ion): 363.070 ([(Co(III)(tren))2(quinS)-H]2+); 304.035 ([Co(II)(tren)
(ClO4)]+).
2.2.4. [(Co(tpa))2(quinS)](ClO4)3 (4)
QuinSH3 (51 mg, 0.16 mmol) was dissolved in 10 mL water and
2 eq. 1M KOH (320 μL), was added giving a purple solution. [Co
(tpa)Cl2]Cl (146 mg, 0.32 mmol) dissolved in 5 mL water was added
and the mixture was stirred at 70 °C for 4 h. 20 mL propanol and
NaClO4 in excess were added. On standing at 4 °C purple crystalline
solid appeared. The solid was filtered and dried in vacuo. Yield: 132 mg
(63%). 1H NMR (400 MHz, d6-DMSO): δ/ppm = 10.31 (d, 1H, AreH
tpa); 9.44 (d, 1H, AreH tpa); 8.83 (s, 1H, AreH quinS); 8.45 (d, 2H,
AreH tpa); 8.41 (d, 2H, AreH); 8.34 (m, 2H, AreH); 8.11–7.98 (m, 6H,
AreH); 7.84 (m, 3H, AreH); 7.77 (t, 4H, AreH); 7.69 (t, 1H, AreH);
7.62 (t, 2H, AreH); 7.56 (t, 2H, AreH); 7,40 (dd, 2H, AreH); 5.73 (dd,
4H, -CH2); 5.33 (d, 4H, -CH2); 5.19 (dd, 4H, -CH2). IR (KBr)/cm−1:
1612, 1450, 1050, 637, 504, 419. Anal. Required for
C50H41Cl3Co2N8O19S∙0.5 propanol∙2 H2O: C, 44.81, H, 3.58, N, 8.12, S,
2.32%. Found: C, 44.82, H, 3.57, N, 7.95, S, 2.53%. MS (ESI, positive
ion): 667.068 ([Co(III)(tpa)(quinS) + H]+); 507.573 ([(Co(III)(tpa))
(quinS)(Co(II)(tpa))]2+); 174.543 ([Co(II)(tpa)]2+).
2.3. NMR, IR and ESI-MS measurements
NMR measurements were carried out using Bruker Avance 400 NMR
spectrometer at room temperature on samples prepared in D2O or/and
in d6-DMSO. Calibration was performed using the signals of the solvents
(2.50 ppm for DMSO and 4.79 ppm for D2O). IR spectra as KBr pellets
were recorded on a Perkin Elmer FTIR Paragon 1000 PC instrument at
the Department of Organic Chemistry, University of Debrecen. ESI-TOF
MS measurements in the positive mode were carried out on a Bruker
micrOTOF-Q instrument at the Department of Applied Chemistry,
University of Debrecen. The concentration of the samples was 10 μg/mL
and the solvent was water or methanol. The instrument was equipped
with an electrospray ion source, where the voltage was 4 kV. The drying
gas was N2. The flow rate was 4 L/min and the drying temperature was
200 °C. The spectra were recorded by means of a digitizer at a sampling
rate of 2 GHz. The mass spectra were calibrated externally, using the
exact masses of clusters [(NaTFA)n + Na]+ generated from the elec-
trosprayed solution of sodium-trifluoroacetate (NaTFA). The spectrums
were evaluated with DataAnalysis 3.4 software from Bruker. The sam-
ples were introduced directly into the ESI with a syringe pump at a flow
rate of 3 μL/min.
2.4. Cyclic voltammetric (CV) studies
Cyclic voltammetric experiments were performed within the voltage
range 0 – −1000 mV, at room temperature in H2O or MeOH, using a
Metrohm 746–747 VA Trace Analyser and BASi Epsilon EClipse
equipped with a three-electrode system, which consists of a Ag/AgCl/
3 M KNO3 reference electrode (E1/2 = +209 mV vs. normal hydrogen
electrode (NHE)), a platinum wire auxiliary electrode (ALS Co. Japan),
and a glassy carbon (CHI104) working electrode. Aqueous solution of
K3[Fe(CN)6] was used to calibrate the system (E1/2 = +0.458 V versus
NHE in 0.50 M KCl) [33]. The samples were degassed before the
measurements using argon gas. The concentration of the complexes was
1 mM, the potential sweep rates were 200 mVs− 1 during the de-
termination of the redox potentials. The supporting electrolyte con-
tentration was 0.20 M in all cases. KNO3 was used in aqueous solutions
and [NBu4][BF4] was used in methanolic solutions. Ligands quinH2 and
quinSH3 were dissolved in water by adding one drop of base (0.2 M
KOH). The samples were dissolved in methanol for pH dependence
studies and pH was adjusted by 0.2 M HCl and 0.2 M KOH.
2.5. Lipophilicity measurements
Distribution coefficients (D7.40) of the compounds were determined
by the traditional shake-flask method in n-octanol/buffered aqueous
solution at pH = 7.40 phosphate buffer saline (PBS) at 25.0 ± 0.2 °C.
Compounds, except for quinH2, were dissolved in n-octanol pre-satu-
rated buffered aqueous phase, and final compound concentration was
20–100 μM. Ligand quinH2 was dissolved in n-octanol pre-saturated by
water in 2 mM concentration. Aqueous buffered phases and water pre-
saturated n-octanolic phases were gently mixed in 1:1, 1:70 (for 3, 4),
or 20:1 (for quinH2) volume ratios with Heidolph Reax 2 overhead
shaker (~20 rpm) for 2 h. The mixtures were centrifuged with
Eppendorf MiniSpin Plus centrifuge (5000 rpm, 3 min). After phase
separation, UV−Vis spectrum of the compound in the aqueous phase
(in the n-octanolic phase in case of quinH2) was compared to that of the
original stock solution and DpH values of the compounds were calcu-
lated according to the following equations:
= ×
V
D
Abs
Abs
1
V
n
pH
(stock.sol.)
(aqueous phase after separation)
(aqueous phase)
( octanol phase) (1)
and for quinH2:
= ×
V
D
Abs
Abs Abs
V
n
pH
(oct.phase after separation)
(stock.sol.) (oct.phase after separation)
(aqueous phase)
( octanol phase) (2)
A Hewlett Packard 8452a diode array spectrophotometer was used
to measure the UV–Vis spectra in the interval 200–500 nm.
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2.6. HSA binding studies
2.6.1. Preparation of stock solutions of HSA and the studied complexes and
ligands
HSA solution was prepared in phosphate buffered saline (PBS)
strictly on the same day when the experiment was performed. Ligand
quinSH3 and all complexes were dissolved in PBS buffer at c.a. 100 μM
concentration. Ligand stock solution of quinH2 was prepared in DMSO
(100 μM). Ligand stock solutions were kept in dark and were used
within 48 h.
2.6.2. UV–Vis spectrophotometric measurements on HSA binding of the
compounds
Two-chamber cuvettes (tandem cells) were utilized to monitor the
interaction between HSA and compounds quinSH3, 1 and 4 in PBS
puffer. One chamber contained 60 μM compound and the other con-
tained 4–120 μM HSA. Spectra were recorded before and after mixing of
the content of the cuvette on an Agilent Cary 8454 diode array spec-
trophotometer in the wavelength range between 190 and 1100 nm.
2.6.3. Spectrofluorometric measurements
PBS puffer was used for sample preparation; and emission spectra
were recorded after 30 min incubation. Three kinds of experiments were
carried out: (i) 1 μM HSA and various amounts of compound (from 0 to
15 eq.) were used for quenching experiments; and (ii) fluorescence of site
markers WF and DG was examined in samples containing 1 μM HSA,
1 μMmarker and 0–15 μM compound; while (iii) intrinsic fluorescence of
the ligands was followed as well applying 1 or 0.5 μM ligand and various
HSA concentrations (0–15 μM). The excitation and emission wavelengths
and applied slit widths are listed in Table S1. Computer program
PSEQUAD was utilized for calculation of formation constants for HSA –
compound adducts as described in our former work [34].
Corrections for self-absorbance and inner filter effect were done as
described in our former work using the formula suggested by Lakowicz
[35,36].
Model calculations on the binding stoichiometry of quinSH3 – HSA
interaction were carried out for models assuming one (I), two (II) or
three (III) available binding sites on the protein. The two binding
constants determined in site marker displacement experiments were
used for model II; model I operates with logK’ = 6.30 (average value of
the two determined constants), while model III contains the two ex-
perimental constant and the average of them assumed for a third site.
Calculations were done with MEDUSA program [37].
3. Results and discussion
3.1. Synthesis and characterization
QuinH2 or quinSH3 and stoichiometric amount of [Co(4 N)Cl2]Cl
(4 N = tren or tpa) precursors were reacted in isopropanol for 1, 2,
Fig. 2. The aromatic region of the 1H NMR spectrum of [(Co(tren))2(quin)](ClO4)4 (1) in D2O. A and C are the supposed structures of the symmetrical isomers while B
is the asymmetrical isomer.
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methanol for 3 and water for 4 in the presence of two eq. base at high
temperature (60–70 °C) for 4 h or overnight. Purple crystalline solid
appeared on cooling at 4 °C by adding bulky ClO4− or PF6− anions to
the reaction mixture. The novel complexes are air stable, soluble in
water in relatively low (0.7–1.0 mM) concentration and stable in aqu-
eous solution at least for 48 h.
The free ligand quinH2 was examined by 1H NMR in d6-DMSO. The
hydroxyl groups appear as one singulet at 12.7 ppm. Resonances of
protons 2 and 3 (see Fig. 1. for the numbering scheme) at 8.25 ppm, 4
and 5 at 7.99 ppm as multiplets and 6, 7 at 7.44 ppm as a singulet in the
spectrum. All of the similar type of protons showed one single peak
each in the spectrum, proving the symmetry of the ligand. By adding
base to the sample all signals of the aromatic protons showed downfield
shift due to deprotonation of the hydroxyl groups. The extent of the
shift was 0.29 ppm in the case of protons 2, 3, 0.15 ppm for 5, 8 and
nearly 0 ppm (0.01 ppm) for 6, 7 due to these latter hydrogens are too
far from the hydroxyl groups.
The signals of the quinizarin as well as the aliphatic tren protons in
the spectra of 1 and 3 complexes are separated well resulting a simple
assignation. For illustration 1H NMR spectrum of 1 is shown in Fig. S1.
Comparing the integrals of the resonances of the 6, 7 protons of qui-
nizarin (around 7.95 ppm) and one of the well separated set of signals
of one CH2 function (around 3.55 ppm) of the tren ligand for instance,
the integration values clearly reveal the dinuclear nature of the com-
plexes formed with both of the ligands. In particular, in Fig. 2. the
aromatic region of 1 indicates that the 5, 8 protons of the coordinated
ligand exhibit resonances at low field due the neighbouring high elec-
tronegativity O donors while the 6, 7 protons of the same ring show
signals at higher field being further apart from these donors. The re-
maining two 2, 3 protons of the quinizarin backbone can be found
around 7.4 ppm. Looking at the above signals of the protons of the
quinizarin backbone in each case three sets of them can be seen. For the
2, 3 protons instead of the expected three singulets, however, two
singulets and a multiplet are detected. These findings indicate that in 1
two symmetrical and one asymmetrical isomers should be present. (This
is also clearly demonstrated by the COSY spectrum shown in Fig. S2.)
This assumption is further supported by comparing the ratio of integrals
of the three isomers for 5, 8 and 6, 7 protons. The structure of the
expected three isomers can also be seen in Fig. 2. As in isomer B the two
Co cores coordinate asymmetrically to the quinizarin the multiplet for
the 2, 3 protons at 7.4 ppm belongs to this isomer and, according to the
integrals, this is the major one among the isomers.
Assignation was more difficult for the tpa complexes (2 and 4) due
to the aromatic character of the three pyridyl arms of the tpa ligand.
The -CH2 groups of tpa appear in the range of 6.00–5.00 ppm. The ratio
of the aromatic and aliphatic hydrogens clearly indicates the formation
of the same type of dinuclear complexes like in case of the tren ana-
logues. Based on the 1H NMR spectra of 2 and 4 (not shown) the large
number of signals in the well separated –CH2 region indicate the pre-
sence of various isomers.
In order to further elucidate the structure of the complexes ESI-MS
analysis in the positive mode was also carried out. In most of the cases
in the mass spectra of the products peaks belonging to both mono and
dinuclear complexes appeared. Based on the results, Co(III) was re-
duced to Co(II) in all of the four novel compounds under ESI-MS con-
ditions. Peaks of precursor ions like [Co(II)(tren)(ClO4)]+ or [Co(II)
(tpa)]2+ appeared in the spectra in most cases. While in the spectra of
quin complexes only the signals of ions containing Co(II) were detected,
for the quinS analogues molecule ions containing Co(III) can also be
identified. Interestingly, in the spectrum of 4 the m/z = 507.573 value
belongs to the [(Co(III)(tpa))(quinS)(Co(II)(tpa))]2+ with different
oxidation state of the two metal ions. All of the mass spectra displayed
the correct isotopic pattern; as a representative example, see Fig. S3.
The identity of the complexes was further proved by the elemental
analysis data. It was found for the quinS complexes that the sulfonic
acid group is deprotonated in both complexes, thus three counter ions
(PF6− for 3 and ClO4− for 4) were required for crystallization. The
results indicate that complexes 1, 2 and 4 also contain water molecules
in their structures. (Despite all our efforts 1 contains some NaClO4
impurity but this did not affect the results of the CV measurements or
HSA binding studies.)
The carbonyl functional groups of the novel complexes involved in
the coordination were also studied by IR spectroscopy. The change of
the absorption band, assigned to υ(C=O) in all of the novel compounds
compared to that of the free ligand quinH3 was observed. The corre-
sponding band at 1630 cm−1 in the spectrum of quinH3 has been
shifted to the region of 1540–1548 cm−1 upon bonding for all four
complexes [38,39]. The shift of this band due to complexation with
other type of metal ion was reported before [40]. These results con-
firmed that the ligands are bound to the cobalt ions via the oxygens of
the carbonyl groups.
3.2. Electrochemical studies
In order to examine the electrochemical properties of the novel
complexes cyclic voltammetric measurements were carried out in the 0
– (−1000) mV voltage range. Since some previous results demonstrated
redox activity of the studied ligands, quinH2 and quinSH3, in this vol-
tage range [9,41] prior to the investigation of the metal complexes,
measurements on the free ligands in aqueous solution were also per-
formed. In agreement with previous literature findings [9,41] both li-
gands showed redox activity. For illustration, representative voltam-
mograms are seen in Fig. S4. The voltammograms revealed reversible
reduction steps in the range (−450)–(−800) mV vs. Ag/AgCl reference
electrode for both of the ligands, but significant differences were also
observed when the results for quinSH3 and quinH2 were compared.
Namely, the anodic and cathodic peak potential values of quinSH3 were
shifted to the less negative voltage region by approximately 150 mV
compared to the non-sulfonated ligand quinH2, due to the electron
withdrawing character of the sulfonate moiety. As it is shown in Fig. S4,
two successive (overlapping) reduction processes were indicated by the
voltammogram of quinSH3 while only one is seen in the case of quinH2.
However, evaluation of the cathodic peak shows the uptake of two
electrons also in this latter case, using the formula published by Guin
et al. [42]. These above discussed differences of the redox character of
the two ligands were also reported by Guin et al. [9,42].
Although, neutral pH is relevant in biological aspect, to get further
information of the redox character of the ligands, in another experi-
ment, pH dependence was also studied. Because of solubility reasons,
quinSH3 ligand was selected for these investigations. The measurements
were carried out in methanol, using [NBu4][BF4] as supporting elec-
trolyte (see details in the Experimental part). Selected voltammograms,
together with the peak potential values are shown in Fig. S5. Compared
to the nearly neutral condition, the voltammograms changed sig-
nificantly under acidic conditions (pH ~ 2), but only slightly by ad-
justing the pH up to ~ 11.5. (Fig. S5). The reversible successive re-
duction steps appear separately at neutral and basic pH, but turn into
one overlapped reversible peak shifted to the less negative potential
region in acidic solution. This tendency is in a good agreement with the
few literature findings [9,43].
Cyclic voltammetric results on the [Co(tren)Cl2]Cl and [Co
(tpa)Cl2]Cl precursor complexes were previously reported by us and
indicated both compounds to show irreversible reduction, but the peak
potential value of the tpa precursor complex was significantly less ne-
gative than that of the tren analogue [44].
Electrochemical behaviour of the four novel ternary complexes were
characterized as well, representative voltammograms recorded in water
(pH ~5) are presented in Fig. 3a and b.
pH-dependence of the redox behaviour was also studied. Selected
CV curves and peak potential values are shown in Fig. S6 and Table S2,
respectively. The results revealed similar pH-dependence for the
ternary complex, [(Co(tren))2(quinS)](PF6)3 (3) as those of the quinSH3
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ligand.
A comparison between the voltammograms of the free ligands and
the corresponding ternary complexes, as well as between those regis-
tered for the tren-containing and tpa-containing complexes in Fig. 3a
and b shows one significant difference. Namely, one extra reversible
process in each of the latter systems compared to the corresponding free
ligand is indicated in the voltammograms in the potential range (−400)
– 0 mV. All the successive reduction steps are more separated for 4,
while appears as one overlapping peak for the other complexes. The
measured cathodic peak potential values of the novel complexes are
summarized in Table 1.
The registered extra peaks indicating reversible redox processes in
the voltammograms most probably belong to the non-dissociated
ternary complex species since none of the possible dissociation products
(quinH2/quinSH2−, [Co(tren)Cl2]+ (Epc = −439 mV) or [Co
(tpa)Cl2]+ (Epc = 72 mV)) displays similar pattern [42]. Similar ob-
servations have been made for the relevant ruthenium containing
complexes [28].
In accordance with earlier reports on [Co(4 N)(O,O)] (4 N = tren or
tpa, O,O = hydroxamato or quinolonato) type complexes, [44,45] the
reduction potentials of tren complexes are more negative than those of
the corresponding tpa containing ones. This difference originates from
the distinct characters of the N donor atoms of the tripodal amines.
While only σ-bonding is possible with the aliphatic N atoms of tren, π-
back-bonding interaction occurs with the aromatic pyridyl N donor
atoms of tpa. Thus a decreased electron density at the cobalt ions in the
complexes of tpa results in species more susceptible for reduction
compared to the corresponding tren analogues. Regarding the appro-
priate quinizarin Co(III) ternary complexes with a given 4 N donor (tren
or tpa) auxiliary ligand and (O,O) coordination of the quinizarin the
obtained cathodic peak potential values are in the same range as those
obtained for the previusly studied hydroxamato or quinolonato com-
plexes with identical (O,O) coordination [44,45].
3.3. Lipophilicity measurements
Lipophilicity of the studied ligands and their complexes has not
reported in the literature yet. The extremities in the lipophilic and
hydrophilic character of quinH2 and the sulfonated complexes required
modified experimental conditions, namely the water-to-octanol volume
ratio was changed from 1:1 in favor of the less efficient solvent phase
(see details in the Experimental part). Table 2 comprises the logarithm
of distribution coefficients (logD7.40) determined at pH 7.40.
Ligand quinH2 appears to be highly lipophilic, while its sulfonated
congener quinSH3 is significantly hydrophilic thanks to the deproto-
nated sulfonate functional group on the molecule. Complexes 1 and 2
show similar and remarkable hydrophilic character that can be due to
the +4 positive charge of the complex cations. For complexes 3 and 4
only a threshold limit (logD7.40 < −3.0) could be estimated. The ex-
treme hydrophilicity of these sulfonate complexes however is not sur-
prising, considering the c.a. 3.5 orders of magnitude difference in D7.40
values obtained for quinH2 and quinSH3.
The result of lipophilicity measurements points out the possible cell
uptake of the active ligand quinH2 via passive transport, while its
complexes require most probably an alternative pathway to enter cells.
3.4. Albumin binding of the ligands and their complexes
HSA is the most abundant transport protein in human blood, pro-
viding three hydrophobic binding pockets (site I, II and III) for various
types of molecules. Albumin binding may not only increase the ap-
parent solubility of a compound but can prevent its early metabolism
and excretion. HSA binding of the compounds was investigated by
means of UV–Vis and direct and indirect spectrofluorometric techniques
at 37 °C. Limited aqueous solubility of quinH2 allowed the
Fig. 3. CV curves registered for [(Co(tren))2(quin)](ClO4)4 (1), [(Co(tpa))2(quin)](ClO4)4 (2), [(Co(tren))2(quinS)](PF6)3 (3) and [(Co(tpa))2(quinS)](ClO4)3 (4) in
water (pH ~5), referenced to Ag/AgCl electrode at a potential sweep rate of 200 mV/s and ccomplex = 1.0 mM.
Table 1
Cathodic peak potential values of the novel ternary complexes in water (pH~
5), referenced to Ag/AgCl electrode at a potential sweep rate of 200 mV/s
and ccomplex = 1.0 mM.
Complex Epc (mV) vs. Ag/AgCl
[(Co(tren))2(quin)](ClO4)4 (1) −340
−649
[(Co(tpa))2(quin)](ClO4)4 (2) −182
−734
[(Co(tren))2(quinS)](PF6)3 (3) −368
−553
−658
[(Co(tpa))2(quinS)](ClO4)3 (4) −78
−193
−506
−677
Table 2
Distribution coefficients (D7.4) determined for
ligands quinH2 and quinSH3 and their Co(III)-
complexes (1–4), at pH = 7.40 (PBS buffer),
25 °C.
logD7.40
quinH2 2.95(3)
quinSH3 −0.55(2)
1 −1.33(2)
2 −1.08(2)
3 <−3.0
4 <−3.0
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implementation of only certain fluorometric measurements.
Global binding of quinSH3, 1 and 4 on HSA was investigated by
UV–Vis spectrophotometry. Fig. 4 shows the spectral changes of
quinSH3 in the presence of increasing HSA concentration. Absorption
maxima are red shifted with an isobestic point at 498 nm, and a new
band develops between 550 and 650 nm. Structural rearrangement or
even partial deprotonation of the ligand (see Fig. S7 for UV–Vis spec-
trum of the completely deprotonated ligand) is probable upon binding
to albumin. The binding takes place fairly fast (within some seconds the
equilibrium was reached) and seems to be completed upon the addition
of< 1 eq. HSA, that strongly suggests the presence of at least two
binding sites for quinSH3 in HSA. On the other hand, complexes 1 and 4
do not show appreciable spectral changes in the presence of the protein
even after 2 h waiting time (see Fig. S8). This phenomenon however
does not exclude binding of the complexes in HSA, since this event
covers more frequently intermolecular, non-covalent interactions that
have little (or not measurable) effect on the UV–Vis spectra of a small
molecule.
As next step binding at site I (IIA subdomain) was studied via
tryptophan (Trp) quenching experiments in the case of quinSH3, 1, 2, 3
and 4. The only Trp (Trp214) in HSA is situated near to site I and can
selectively be excited at λ = 295 nm. As Fig. 5 shows Trp exerts strong
fluorescence around 340 nm that can be quenched by a binding event at
or close to site I [46–48]. Quenching curves in Fig. 5 suggest con-
siderable binding of quinSH3 at this site, while complexes 1–4 could not
quench the fluorescence of Trp, and consequently may not bind here.
Solubility problems of quinH2 hindered the execution of quenching and
marker displacement measurements with this ligand. A conditional
binding constant logK'quench = 5.92(1) can be computed by the pro-
gram PSEQUAD for the quinSH3 − site I interaction [34]. Binding af-
finity of quinSH3 at site I was determined by WF displacement experi-
ments as well. Here competition of the two compounds for site I was
revealed again and a similar binding constant (logK’ = 6.14(1)) could
be calculated. Complexes 1–4, at the same time, do not compete with
WF for site I, which is in accordance with the findings of quenching
experiments.
Site marker DG was utilized to follow binding at the other main
binding pocket site II (IIIA subdomain). High extent of quinSH3 binds to
site II; the calculated affinity logK’ = 6.45 (2) exceeds reported binding
strength of diazepam that is a well-known high-affinity ligand of site II
(logK = 5.6) [46]. The metal complexes do not show binding at site II.
The studied ligands quinSH3 and quinH2 possess moderate intrinsic
fluorescence favorably not overlapping by that of HSA (see Fig. S9); and
effect of the protein on this fluorescence was investigated as well.
Samples contained ligands in highly diluted solution (1.0 and 0.5 μM
for quinSH3 and quinH2 respectively) and various equivalents of HSA,
which allowed to study the HSA binding of quinH2 itself. Fig. 6a shows
the intensity changes of quinSH3 in the presence of the protein and an
unequivocal decrease in the intensity can be observed. Albumin
binding, providing a solvent protected non-polar environment often
enhances fluorescence of a small-molecule. UV–Vis experiments how-
ever, formerly suggested structural changes, even partial deprotonation
of quinSH3 upon binding to HSA. Besides, fluorescence measurements
reveal negligible fluorescence of the deprotonated form of quinSH3
(Fig. S9). Namely, assisted deprotonation of quinSH3 upon binding to
HSA is a possible explanation of the unusual fluorescence quenching
effect of the protein on the ligand's intrinsic fluorescence.
Model calculations were performed with the help of binding con-
stants determined for sites I and II in order to get an insight into the
binding stoichiometry between HSA and this ligand. In Fig. 6 the two-
site model (assuming binding at both sites I and II) gives the best fit to
the experimental data, while one-site or three-site models deviate
considerably from those. In all, high affinity binding of two equivalents
of quinSH3 is probable on HSA, but existence of a low-affinity
(logK < 5) third site cannot be excluded. The emission intensity of
quinH2 is quenched as well upon addition of HSA (see Fig. 6), however
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Fig. 4. UV–Vis absorbance spectra recorded for quinSH3 in the absence and presence of HSA in various concentrations (A), and absorbance values followed at 460 nm
(Δ) and 530 nm (●) in this system, clig = 30 μM, pH = 7.40 (PBS), 37 °C.
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Fig. 5. Trp214 fluorescence spectra of HSA in the presence of increasing quinSH3 concentrations (0–15 μM) (A) and normalized fluorescence quenching curves
registered at λEM = 350 nm for quinSH3 (●), 1 (◊), 2 (□), 3 (Δ) and 4 (○) at various compound-to-HSA ratios, cHSA = 1 μM; λEX = 295 nm; pH = 7.40 (PBS), 37 °C.
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its protracted quenching curve assumes considerably lower affinity
and/or less accessible binding sites for quinH2 compared to that of
quinSH3.
All in all, both ligands bind to HSA, however in different manner.
QuinSH3 has two high affinity binding sites (at sites I and II) on al-
bumin, while quinH2 shows lower affinity towards the protein. The
different affinity of the two types of ligands can be interpreted by the
negative charge (− and/or 2−) of quinSH3 at pH 7.4 that may con-
tribute to the stronger binding on HSA of this ligand over the neutral
quinH2. The appropriate Co(III)-complexes of the two ligands do not
seem to bind to HSA.
4. Conclusions
Based on their thermodynamic stability, kinetic inertness and redox
features the synthesized quinizarin-containing ternary cobalt(III) com-
plexes may serve as models for anthracycline type drug chaperons being
able to selectively release the drug molecules in hypoxic cancer tissues.
Structural characterization of the complexes supports the formation of
dinuclear species being present in various binding isomers. For 1 the
presence of two symmetrical and one asymmetrical isomer was con-
fimed by detailed NMR studies. Cyclic voltammetric results indicate
redox activity of the ligands quinH2 and quinSH3. At the same time for
the Co(III) complexes further reversible processes were detected.
Reversible reduction for the tren containing complexes occurs in the
potential range of biological relevance (−200 to −400 mV). HSA
binding studies of the free ligands as well as the Co(III) complexes re-
vealed that quinSH3 interacts with hydrophobic pockets site I and II of
the protein, while for quinH2 a significantly lower affinity towards the
protein was demonstrated. On the contrary, complexes 1–4 did not
exhibit significant binding to HSA. Based on the reduction potential
values the studied complexes may selectively be reduced under hypoxic
conditions and both the quin (or anthracycline) ligands and the Co(II)
formed, by initiating ROS formation, can exert they biological effect.
Currently further biological studies are in progress with the novel
ternary complexes to obtain further information on their in vitro effi-
cacy.
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